Radiopharma ɑ-emitters, AZ’s Galbraith and LNPs — a BioCentury podcast

Plus the latest data from Roche in the oral obesity race

Alpha-emitting isotopes are the latest trend in the hot radioligand space, but there’s debate about which isotope offers the best attributes for optimizing safety and efficacy, as well as manufacturing and distribution. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the benefits and challenges that come with developing radiopharmaceuticals using lead-212 versus its more well-known counterpart actinium-225.

They also discuss Editor-in-Chief Simone Fishburn’s conversation with Susan Galbraith, EVP of Oncology R&D at AstraZeneca plc (LSE:AZN; NASDAQ:AZN), about the future of cancer research and the pharma’s comeback in the space.

The conversation also dives into the state of innovation in targeting lipid nanoparticles to specific tissues beyond the liver, and the most recent oral GLP-1 obesity data from Roche (SIX:ROG; OTCQX:RHHBY). 

For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com.